ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

GSK Inks Pact With Amplimmune

by Lisa M. Jarvis
August 9, 2010 | APPEARED IN VOLUME 88, ISSUE 32

GlaxoSmithKline will pay up to $508 million for access to Amplimmune’s protein fusion therapies that target PD-1, a protein involved in regulating T-cell-mediated immune responses. Rockville, Md.-based Amplimmune scores $23 million up front and is eligible for milestones as its lead candidate, AMP-224, progresses in clinical trials. Amplimmune expects to file an Investigational New Drug Application with FDA and start a Phase I clinical trial of AMP-224 for treatment of cancer in 2011.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment